Literature DB >> 28949775

Evaluation of sFLT1 protein levels in human eyes with the FLT1 rs9943922 polymorphism.

Kathleen R Chirco1, Carly J Lewis1, Todd E Scheetz1, Rebecca M Johnston1, Budd A Tucker1, Edwin M Stone1, John H Fingert1, Robert F Mullins1.   

Abstract

PURPOSE: Age-related macular degeneration (AMD) is a devastating disease characterized by central vision impairment in individuals with advanced age. Neovascular AMD is a form of end-stage disease in which choroidal vessel outgrowth occurs beneath the retina. While many hypotheses have been raised as to what triggers the formation of pathological choroidal neovascular membranes, the exact mechanism for their initiation remains unresolved. Polymorphisms in the FLT1 gene have previously been associated with neovascular AMD risk, including the rs9943922 single nucleotide polymorphism (SNP). Here, we aimed to determine the association between the high-risk FLT1 genotype and FLT1 protein levels in human retina or retinal pigment epithelium (RPE)/choroid tissue.
METHODS: Retina and RPE/choroid tissue from 10 human donor eyes was selected from a collection of eyes genotyped for the rs9943922 SNP. Differences in soluble and membrane bound FLT1 protein levels were assessed for retina versus RPE/choroid donor tissue using ELISA and Western blotting analyses. Genotype-associated changes in FLT1 protein levels were also evaluated.
RESULTS: We found soluble FLT1 levels in the RPE/choroid tissue to be approximately three times higher than that of the retina (p < 0.001), while both samples have similar levels of the membrane bound form. When tissue with the rs9943922 SNP was compared with controls, no significant genotypic differences in FLT1 protein levels were observed.
CONCLUSIONS: Based on these data, we conclude that the rs9943922 SNP in the FLT1 gene does not result in a large difference in FLT1 protein levels, regardless of whether it is the soluble or the membrane bound form.

Entities:  

Keywords:  Age-related macular degeneration; FLT1; VEGF receptor; choroid; retina

Mesh:

Substances:

Year:  2017        PMID: 28949775      PMCID: PMC5751420          DOI: 10.1080/13816810.2017.1369550

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  27 in total

Review 1.  Age-related macular degeneration.

Authors:  Rama D Jager; William F Mieler; Joan W Miller
Journal:  N Engl J Med       Date:  2008-06-12       Impact factor: 91.245

Review 2.  Relationship between the complement system, risk factors and prediction models in age-related macular degeneration.

Authors:  Nalini S Bora; Bharati Matta; Valeriy V Lyzogubov; Puran S Bora
Journal:  Mol Immunol       Date:  2014-07-26       Impact factor: 4.407

3.  Adenosine modifies the balance between membrane and soluble forms of Flt-1.

Authors:  Frederique Leonard; Yvan Devaux; Melanie Vausort; Isabelle Ernens; Magali Rolland-Turner; Daniel R Wagner
Journal:  J Leukoc Biol       Date:  2011-03-29       Impact factor: 4.962

4.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration.

Authors:  Zhenglin Yang; Nicola J Camp; Hui Sun; Zongzhong Tong; Daniel Gibbs; D Joshua Cameron; Haoyu Chen; Yu Zhao; Erik Pearson; Xi Li; Jeremy Chien; Andrew Dewan; Jennifer Harmon; Paul S Bernstein; Viji Shridhar; Norman A Zabriskie; Josephine Hoh; Kimberly Howes; Kang Zhang
Journal:  Science       Date:  2006-10-19       Impact factor: 47.728

6.  FLT1 genetic variation predisposes to neovascular AMD in ethnically diverse populations and alters systemic FLT1 expression.

Authors:  Leah A Owen; Margaux A Morrison; Jeeyun Ahn; Se Joon Woo; Hajime Sato; Rosann Robinson; Denise J Morgan; Fani Zacharaki; Marina Simeonova; Hironori Uehara; Usha Chakravarthy; Ruth E Hogg; Balamurali K Ambati; Maria Kotoula; Wolfgang Baehr; Neena B Haider; Giuliana Silvestri; Joan W Miller; Evangelia E Tsironi; Lindsay A Farrer; Ivana K Kim; Kyu Hyung Park; Margaret M DeAngelis
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-08       Impact factor: 4.799

Review 7.  Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy.

Authors:  S Scott Whitmore; Elliott H Sohn; Kathleen R Chirco; Arlene V Drack; Edwin M Stone; Budd A Tucker; Robert F Mullins
Journal:  Prog Retin Eye Res       Date:  2014-12-05       Impact factor: 21.198

8.  Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.

Authors:  Benjamin Bakall; James C Folk; H Culver Boldt; Elliott H Sohn; Edwin M Stone; Stephen R Russell; Vinit B Mahajan
Journal:  Am J Ophthalmol       Date:  2013-05-22       Impact factor: 5.258

9.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Authors:  Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2012-10-17       Impact factor: 12.079

10.  Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1.

Authors:  Ling Luo; Hironori Uehara; Xiaohui Zhang; Subrata K Das; Thomas Olsen; Derick Holt; Jacquelyn M Simonis; Kyle Jackman; Nirbhai Singh; Tadashi R Miya; Wei Huang; Faisal Ahmed; Ana Bastos-Carvalho; Yun Zheng Le; Christina Mamalis; Vince A Chiodo; William W Hauswirth; Judit Baffi; Pedro M Lacal; Angela Orecchia; Napoleone Ferrara; Guangping Gao; Kim Young-Hee; Yingbin Fu; Leah Owen; Romulo Albuquerque; Wolfgang Baehr; Kirk Thomas; Dean Y Li; Kakarla V Chalam; Masabumi Shibuya; Salvatore Grisanti; David J Wilson; Jayakrishna Ambati; Balamurali K Ambati
Journal:  Elife       Date:  2013-06-18       Impact factor: 8.140

View more
  1 in total

1.  Gene polymorphisms and serum levels of sVEGFR-1 in patients with systemic lupus erythematosus.

Authors:  Zhi-Chao Yuan; Wang-Dong Xu; Jia-Min Wang; Qian Wu; Jie Zhou; An-Fang Huang
Journal:  Sci Rep       Date:  2020-09-14       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.